Salyka Sengsayadeth, MD
Hematology & Oncology · Nashville, TNNPI 1619024429
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $320 of the $471 with a category attached, or 68.0%. AstraZeneca accounts for 67.0% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for hematology & oncology clinicians in TN, where the typical reported total is $5,575.
Across 8 payments — averaging $58.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$316
- Taiho Oncology, Inc.$138
- Stemline Therapeutics Inc.$17
Across 126 payments — averaging $8265.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$412K
- Amgen$336K
- AstraZeneca$255K
- Novartis$23K
- Takeda Pharmaceuticals U.S.A., Inc.$16K
What the payments were for
- Speaking & faculty fees$32068%
- Travel & lodging$13428%
- Education$174%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $316 |
| Taiho Oncology, Inc. | 4 | $138 |
| Stemline Therapeutics Inc. | 1 | $17 |
How this compares
$471 in reported general payments places this provider in the 15th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 34 | $608,805 |
| PomalystPomalidomide | 23 | $537,848 |
| Lenalidomide | 17 | $189,500 |
| EliquisApixaban | 14 | $10,038 |
| ValacyclovirValacyclovir Hcl | 51 | $1,904 |
| Dexamethasone | 22 | $283 |
| Gabapentin | 36 | $267 |
| Mirtazapine | 11 | $261 |
| Duloxetine Hcl | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Nashville
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
- Olalekan OluwoleNashville$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.